newsfilter
← Latest News
GlobeNewswire·

Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial tr